Companies / enGene Therapeutics Inc. / Activity
Activity — enGene Therapeutics Inc.
13 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Brunk Gerald a Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jun 16, 2026 | Astley-Sparke Philip Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jun 16, 2026 | Glickman Richard M Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jun 16, 2026 | Hastings Paul J Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jun 16, 2026 | Zoth Lota S. Director | Grant | Stock Option (Right to Buy) | — | +31K | 31,000 0.05% of shares | low |
| Jan 30, 2026 | Cheung Anthony Tzeyew Executive | Grant | Stock Option (Right to Buy) | — | +195K | 195,000 0.29% of shares | low |
| Jan 30, 2026 | Nichols Alexander Julian Executive | Grant | Stock Option (Right to Buy) | — | +195K | 195,000 0.29% of shares | low |
| Jan 30, 2026 | Connolly Joan Executive | Grant | Stock Option (Right to Buy) | — | +195K | 195,000 0.29% of shares | low |
| Jan 30, 2026 | Boyd Matthew Ross Executive | Grant | Stock Option (Right to Buy) | — | +195K | 195,000 0.29% of shares | low |
| Jan 30, 2026 | Giguere Lee Executive | Grant | Stock Option (Right to Buy) | — | +195K | 195,000 0.29% of shares | low |
| Jan 30, 2026 | Buck Jill Executive | Grant | Stock Option (Right to Buy) | — | +195K | 195,000 0.29% of shares | low |
| Jan 30, 2026 | Cooper Ronald Harold Wilfred CEO | Grant | Stock Option (Right to Buy) | — | +801K | 801,000 1.20% of shares | low |
| Jan 30, 2026 | Daws D. Ryan Executive | Grant | Stock Option (Right to Buy) | — | +220K | 220,000 0.33% of shares | low |